Pfizer and Clear Creek Bio will collaborate to research SARS-CoV-2 papain-like protease (PLpro) inhibitors, with the aim of developing an oral treatment for COVID-19. It’s still in its discovery phase, but if successful, Pfizer said it will pay the biotech company “an undisclosed upfront payment,” milestone payments and royalties, according to a Dec. 6 news release.
The enzyme PLpro is “a unique viral protease that cleaves important host regulators of innate immunity such as ISG15, resulting in dampened antiviral immune mechanisms,” according to Clear Creek Bio’s website.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
